```html

Xanthine‑Induced Kidney Stones

Overview

Xanthine‑induced kidney stones are a rare form of metabolic stone disease caused by the accumulation of xanthine, a purine‑base intermediate in the degradation of nucleic acids. The condition usually stems from a hereditary enzyme deficiency—xanthine oxidase deficiency or hypoxanthine‑guanine phosphoribosyltransferase (HPRT) deficiency—which leads to excessive urinary xanthine that can precipitate into crystals and, over time, form stones.

Who it affects: The disease is most often diagnosed in children or young adults, but cases have been reported in older adults who acquire the defect secondary to medication (e.g., long‑term high‑dose allopurinol) or rare acquired enzyme inhibition. Both sexes are affected, though a slight male predominance (≈55 % of reported cases) has been noted.

Prevalence: Xanthine stones account for < 1 % of all kidney‑stone presentations (estimated 0.5–1 case per 10 000 people) and are considered “orphan” diseases. The exact global incidence is unknown because many patients remain undiagnosed; estimates from the International Society of Nephrology place the prevalence of hereditary xanthinuria at 1–2 per 100 000 population.<sup>1</sup>

Symptoms

Symptoms may be intermittent and often mimic those of other stone types. Common manifestations include:

• Flank pain – sudden, severe, colicky pain radiating from the back to the groin.
• Hematuria – pink, red, or brown urine; may be microscopic.
• Urinary urgency or frequency – irritation of the ureter or bladder.
• Nausea and vomiting – due to visceral pain stimulation.
• Fever or chills – suggestive of secondary infection (see complications).
• Kidney swelling (hydronephrosis) – detectable on imaging, may cause dull achiness.
• Recurrent urinary tract infections (UTIs) – especially with obstructive stones.
• Episodes of “stone‑colic” without radiographic findings – small crystals may pass unnoticed.

In pediatric patients, the first sign may be an unexplained growth delay or abdominal pain that resolves after stone passage.

Causes and Risk Factors

Primary cause – metabolic enzyme defects

• Xanthinuria type I – autosomal recessive deficiency of xanthine oxidase (XDH gene).
• Xanthinuria type II – deficiency of both xanthine oxidase and aldehyde oxidase (MOCOS gene).
• HPRT deficiency (Lesch‑Nyhan syndrome) – leads to excess hypoxanthine → xanthine conversion.

Secondary (acquired) causes

• Long‑term high‑dose allopurinol or febuxostat causing “over‑inhibition” of xanthine oxidase.
• Severe gastrointestinal malabsorption with rapid nucleic‑acid turnover (e.g., short‑bowel syndrome).
• Extremely high purine diets (organ meats, anchovies, sardines) in genetically susceptible individuals.

Risk factors

• Family history of xanthinuria or Lesch‑Nyhan syndrome.
• Consanguineous parentage (increases autosomal recessive inheritance).
• Chronic dehydration – low urine volume concentrates xanthine.
• Acidic urine (pH < 5.5) favors precipitation of xanthine crystals.
• Use of medications that raise purine load (e.g., 6‑mercaptopurine, azathioprine).

Diagnosis

Diagnosing xanthine‑induced stones requires a combination of clinical suspicion, imaging, and specialized laboratory testing.

1. Urinalysis & Stone Analysis

• Urine dipstick – may show hematuria; standard dipsticks do not detect xanthine.
• Microscopic examination – characteristic “yellow‑brown” amorphous crystals that are birefringent under polarized light.
• Stone composition – infrared spectroscopy or X‑ray diffraction confirms > 95 % xanthine.

2. Blood Tests

• Serum uric acid – usually low or normal (contrast with uric acid stones where it is high).
• Renal function panel – creatinine, eGFR to assess baseline kidney health.
• Genetic testing – sequencing of XDH, MOCOS, or HPRT genes confirms hereditary forms.

3. Metabolic Urine Tests

24‑hour urine collection for quantitative measurement of xanthine, hypoxanthine, and uric acid. Elevated xanthine (> 500 mg/24 h) strongly supports the diagnosis.

4. Imaging

• Non‑contrast CT scan – gold standard; detects radiolucent xanthine stones (often low density).
• Ultrasound – useful in children or pregnant patients; shows echogenic foci with posterior shadowing.
• Plain abdominal X‑ray – limited utility; xanthine stones are often radiolucent.

5. Differential Diagnosis

Rule out other radiolucent stones (cystine, uric acid) and non‑stone causes of flank pain.

Treatment Options

Management targets stone removal, prevention of new stones, and correction of the underlying metabolic abnormality.

1. Acute Stone Passage

• Hydration – aim for urine output > 2 L/day (≈ 2.5 L fluid intake).
• Medical expulsive therapy – α‑blockers (tamsulosin 0.4 mg daily) can facilitate ureteral stone passage.
• Pain control – NSAIDs (ibuprofen 400‑600 mg q6‑8h) or opioids if needed.

2. Surgical/Procedural Interventions

• Extracorporeal shock wave lithotripsy (ESWL) – effective for stones < 2 cm and when stone composition is known.
• Ureteroscopy with laser lithotripsy – preferred for distal ureteral stones or when ESWL fails.
• Percutaneous nephrolithotomy (PCNL) – for large (> 2 cm) or staghorn‑type xanthine calculi.

3. Long‑Term Metabolic Management

• Increase fluid intake – maintain urine specific gravity < 1.010.
• Alkali therapy – potassium citrate 10‑30 mmol 2–3 times daily raises urine pH, reducing crystal formation.
• Low‑purine diet – limit organ meats, sardines, anchovies, and high‑fructose corn syrup.
• Allopurinol reduction – if the patient is on high‑dose allopurinol, consider dose taper under physician supervision.
• Vitamin B2 (riboflavin) supplementation – may enhance residual xanthine‑oxidase activity in type I patients (dose 10–20 mg/day, limited evidence).

4. Pharmacologic Options (Experimental)

Research is ongoing on enzyme‑replacement or gene‑therapy approaches; currently these are only available in clinical‑trial settings.

Living with Xanthine‑Induced Kidney Stones

Daily Management Tips

• Fluid schedule – sip water throughout the day; a handy target is 250 mL every hour.
• Urine monitoring – use test strips for specific gravity; aim for 1.005–1.010.
• Diet log – record high‑purine foods; apps like MyFitnessPal can flag purine content.
• Medication adherence – never skip potassium citrate or alkali therapy.
• Regular follow‑up – 6‑month metabolic labs and imaging in the first two years, then annually if stable.
• Physical activity – moderate exercise boosts overall hydration and reduces stone risk.

Psychosocial Considerations

Because the disorder is rare, patients may feel isolated. Connecting with support groups such as the International Stone Association or rare‑disease advocacy networks can provide emotional backup and practical tips.

Prevention

Preventive strategies focus on diluting urinary xanthine and minimizing its precipitation:

• Hydration – at least 2–3 L of fluid daily, higher in hot climates or during exercise.
• Urine alkalinization – maintain pH > 6.5 with potassium citrate or sodium bicarbonate.
• Low‑purine diet – < 100 mg of purines per day (≈ ½ cup of beans is a practical benchmark).
• Avoid fructose‑rich sodas – fructose enhances purine metabolism.
• Limit vitamin C megadoses – high doses (> 1 g/day) increase oxalate, potentially compounding stone risk.
• Regular metabolic monitoring – yearly 24‑hour urine xanthine, especially after any medication change.

Complications

If left untreated, xanthine stones can lead to serious sequelae:

• Recurrent obstruction – chronic hydronephrosis may cause permanent renal parenchymal loss.
• Chronic kidney disease (CKD) – up to 15 % of long‑standing cases progress to CKD stage 3 or higher.<sup>2</sup>
• Infection – obstructed urinary tracts are a nidus for urosepsis; Escherichia coli and Proteus species are common.
• Stone growth into staghorn formations – occupies large portions of the collecting system, often requiring surgical removal.
• Secondary metabolic disturbances – low uric acid may mask gout risk but can impair antioxidant capacity.

When to Seek Emergency Care

---

Sources: <sup>1</sup> International Society of Nephrology. “Rare Metabolic Kidney Stone Disorders.” 2023; <sup>2</sup> Mayo Clinic. “Kidney stones – complications.” Updated 2022; CDC. “Kidney Stone Surveillance” 2021; Cleveland Clinic. “Xanthine stones – diagnosis and treatment.” 2024; NIH Genetic and Rare Diseases Information Center (GARD) entry on Xanthinuria.

```